IF 21 1区 医学 Q1 HEMATOLOGY Blood Pub Date : 2025-01-06 DOI:10.1182/blood.2024026211
Shruti Gupta, Sarah Allison Kaunfer, Kevin L Chen, Julie-Alexia Dias, Anitha Vijayan, Arun Rajasekaran, Jason Prosek, Huong L Truong, Anthony Wood, Claude Bassil, Amanda DeMauro Renaghan, Chintan V Shah, Jingjing Zhang, Ilya Glezerman, Christopher Carlos, Katherine Kelly, Christopher J Passero, Jan Drappatz, Ala Abudayyeh, Daniel Shin, C John Sperati, Bradley J Yelvington, Swetha Rani Kanduri, Javier A Neyra, Daniel Edmonston, Anushree C Shirali, Anip Bansal, Abdallah Geara, Zain Mithani, Susan L Ziolkowski, Arash Rashidi, Jonathan Jakubowski, Ashwini Pujari, David A Bond, Emily K Dotson, Sarah A Wall, John T Patton, Jason N Barreto, Sandra M Herrmann, Mohammad Salman Sheikh, Rachid C Baz, Jae Hui Lee, Nicholas Lucchesi, Michael Kolman, Muhammad Ahsan Rasheed, Afsheen Afzal, Dasol Kang, Amrita Mahesh, Raymond Hsu, Anthony Nicolaysen, Kibrewessen Tefera, Claire Schretlen, Ryan M Miller, Juan Carlos Q Velez, Alexander H Flannery, Abinet M Aklilu, Shuchi Anand, Soniya Chandrasekhara, Vicki Donley, Ashka Patel, Jian Ni, Shobana Krishnamurthy, Rafia Ali, Osman A Yilmam, Sophia L Wells, Jessica L Ortega, Olivia L Green-Lingren, Rebecca Karp Leaf, Meghan E Sise, Lakshmi Nayak, Ann S LaCasce, Nelson Leung, David E Leaf
{"title":"Glucarpidase for Treatment of High-Dose Methotrexate Toxicity.","authors":"Shruti Gupta, Sarah Allison Kaunfer, Kevin L Chen, Julie-Alexia Dias, Anitha Vijayan, Arun Rajasekaran, Jason Prosek, Huong L Truong, Anthony Wood, Claude Bassil, Amanda DeMauro Renaghan, Chintan V Shah, Jingjing Zhang, Ilya Glezerman, Christopher Carlos, Katherine Kelly, Christopher J Passero, Jan Drappatz, Ala Abudayyeh, Daniel Shin, C John Sperati, Bradley J Yelvington, Swetha Rani Kanduri, Javier A Neyra, Daniel Edmonston, Anushree C Shirali, Anip Bansal, Abdallah Geara, Zain Mithani, Susan L Ziolkowski, Arash Rashidi, Jonathan Jakubowski, Ashwini Pujari, David A Bond, Emily K Dotson, Sarah A Wall, John T Patton, Jason N Barreto, Sandra M Herrmann, Mohammad Salman Sheikh, Rachid C Baz, Jae Hui Lee, Nicholas Lucchesi, Michael Kolman, Muhammad Ahsan Rasheed, Afsheen Afzal, Dasol Kang, Amrita Mahesh, Raymond Hsu, Anthony Nicolaysen, Kibrewessen Tefera, Claire Schretlen, Ryan M Miller, Juan Carlos Q Velez, Alexander H Flannery, Abinet M Aklilu, Shuchi Anand, Soniya Chandrasekhara, Vicki Donley, Ashka Patel, Jian Ni, Shobana Krishnamurthy, Rafia Ali, Osman A Yilmam, Sophia L Wells, Jessica L Ortega, Olivia L Green-Lingren, Rebecca Karp Leaf, Meghan E Sise, Lakshmi Nayak, Ann S LaCasce, Nelson Leung, David E Leaf","doi":"10.1182/blood.2024026211","DOIUrl":null,"url":null,"abstract":"<p><p>High-dose methotrexate (MTX) results in high rates of acute kidney injury (AKI), neutropenia, and hepatotoxicity. Glucarpidase is a recombinant enzyme that cleaves MTX, but clinical data supporting its use are scarce. We examined the association between glucarpidase administration and outcomes in adults with MTX-AKI from 28 cancer centers across the U.S using a sequential target trial emulation framework. The primary end point was kidney recovery at hospital discharge, defined as survival to discharge with serum creatinine <1.5-fold baseline and without dialysis-dependence. Key secondary end points were time-to-kidney recovery, neutropenia and transaminitis on day 7, and time-to-death. Using multivariable logistic and Cox regression models, we compared outcomes in patients who received glucarpidase within 4 days following MTX initiation with those in patients who did not. Among 708 patients with MTX-AKI, 209 (29.5%) received glucarpidase. Overall, 183 (25.8%) had a primary end point event. Glucarpidase receipt was associated with a 2.70-fold higher adjusted odds of kidney recovery (95% CI, 1.69-4.31) compared to no glucarpidase receipt. Patients treated with glucarpidase also had faster time-to-kidney recovery (adjusted hazard ratio [aHR], 1.88, 95% CI, 1.18-3.33) and lower risks of grade ≥2 neutropenia (adjusted odds ratio [aOR], 0.50, 95% CI, 0.28-0.91) and grade ≥2 transaminitis (aOR, 0.50, 95% CI, 0.28-0.91) on day 7. There was no difference in time-to-death (aHR, 0.76; 95 CI, 0.49-1.18). These data suggest glucarpidase may improve both renal and extrarenal outcomes in patients with MTX-AKI.</p>","PeriodicalId":9102,"journal":{"name":"Blood","volume":" ","pages":""},"PeriodicalIF":21.0000,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1182/blood.2024026211","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

大剂量甲氨蝶呤(MTX)导致急性肾损伤(AKI)、中性粒细胞减少症和肝毒性的发生率很高。葡萄糖苷酶是一种能裂解 MTX 的重组酶,但支持其使用的临床数据却很少。我们采用顺序目标试验仿真框架,研究了来自美国 28 个癌症中心的 MTX-AKI 成人患者服用葡萄糖苷酶与疗效之间的关系。主要终点是出院时的肾功能恢复情况,即出院时血清肌酐
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Glucarpidase for Treatment of High-Dose Methotrexate Toxicity.

High-dose methotrexate (MTX) results in high rates of acute kidney injury (AKI), neutropenia, and hepatotoxicity. Glucarpidase is a recombinant enzyme that cleaves MTX, but clinical data supporting its use are scarce. We examined the association between glucarpidase administration and outcomes in adults with MTX-AKI from 28 cancer centers across the U.S using a sequential target trial emulation framework. The primary end point was kidney recovery at hospital discharge, defined as survival to discharge with serum creatinine <1.5-fold baseline and without dialysis-dependence. Key secondary end points were time-to-kidney recovery, neutropenia and transaminitis on day 7, and time-to-death. Using multivariable logistic and Cox regression models, we compared outcomes in patients who received glucarpidase within 4 days following MTX initiation with those in patients who did not. Among 708 patients with MTX-AKI, 209 (29.5%) received glucarpidase. Overall, 183 (25.8%) had a primary end point event. Glucarpidase receipt was associated with a 2.70-fold higher adjusted odds of kidney recovery (95% CI, 1.69-4.31) compared to no glucarpidase receipt. Patients treated with glucarpidase also had faster time-to-kidney recovery (adjusted hazard ratio [aHR], 1.88, 95% CI, 1.18-3.33) and lower risks of grade ≥2 neutropenia (adjusted odds ratio [aOR], 0.50, 95% CI, 0.28-0.91) and grade ≥2 transaminitis (aOR, 0.50, 95% CI, 0.28-0.91) on day 7. There was no difference in time-to-death (aHR, 0.76; 95 CI, 0.49-1.18). These data suggest glucarpidase may improve both renal and extrarenal outcomes in patients with MTX-AKI.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Blood
Blood 医学-血液学
CiteScore
23.60
自引率
3.90%
发文量
955
审稿时长
1 months
期刊介绍: Blood, the official journal of the American Society of Hematology, published online and in print, provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. Primary research articles will be published under the following scientific categories: Clinical Trials and Observations; Gene Therapy; Hematopoiesis and Stem Cells; Immunobiology and Immunotherapy scope; Myeloid Neoplasia; Lymphoid Neoplasia; Phagocytes, Granulocytes and Myelopoiesis; Platelets and Thrombopoiesis; Red Cells, Iron and Erythropoiesis; Thrombosis and Hemostasis; Transfusion Medicine; Transplantation; and Vascular Biology. Papers can be listed under more than one category as appropriate.
期刊最新文献
CpG island methylator phenotype classification improves risk assessment in pediatric T-cell Acute Lymphoblastic Leukemia. Dual Biological Role and Clinical Impact of De Novo Chromatin Activation in Chronic Lymphocytic Leukemia. Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel CRBN-binding agents in myeloma. GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia. Functional assessment of genetic variants in thrombomodulin detected in patients with bleeding and thrombosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1